Adenocarcinoma of the pancreas is a formidable disease.
Patients in the United States with resected disease are usually offered adjuvant chemoradiation. This practice is supported by the National Comprehensive Cancer Network.
|Adjuvant therapy regimen as a standard of care is lacking.|
|Annals of Surgical Oncology|
In this study, researchers from Buffalo, New York, reviewed 7 selected series to evaluate the efficacy of adjuvant therapy for patients who had resected adenocarcinoma of the pancreas.
The researchers used current evidence-based analysis to demonstrate that an adjuvant therapy regimen as a standard of care is lacking.
The team found that this therapy should be used judiciously as its benefit is confined to only a fraction of patients treated by complete resection (R0).
Furthermore, patients with residual microscopic disease (R1) derived negligible benefits from the treatment.
Dr Quyen Chu's team concluded, "Given the financial constraints and the small effect that current therapies have on this fatal disease, clinicians should concentrate on developing novel therapies and new paradigms to address this age-old problem".